Medical Condition News

RSS

$16 million federal stimulus funds establish Seattle as national hub for cancer research

Researchers at Fred Hutchinson Cancer Research Center, Group Health Research Institute and the University of Washington schools of Public Health and Pharmacy have been selected to lead four projects backed by approximately $16 million in federal stimulus funding for comparative-effectiveness research in cancer.

7 Oct 2009

Cognitive behavioral therapy effective for bulimia and binge eating disorders

Although most people with bulimia and binge eating disorders wait many years before seeking help, a new review shows that psychological treatment can make a large difference — and that cognitive behavioral therapy (CBT) is the most effective talk therapy for these disorders.

6 Oct 2009

FDA provides 510(k) clearance for Boston Scientific's WallFlex Biliary RX covered stents

Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its WallFlex(®) Biliary RX fully and partially covered stents for the palliative treatment of malignant bile duct strictures. The WallFlex Biliary RX uncovered stent was cleared by the FDA in 2006.

6 Oct 2009

US Army grants BioDelivery Sciences $1.3M for investigating Bioral Amphotericin B

BioDelivery Sciences International, Inc. has received a $1.3 million grant from the Walter Reed Army Institute of Research for Bioral Amphotericin B, an oral formulation of the fungicidal treatment amphotericin B in BDSI’s patented Bioral drug delivery technology, to further study the formulation in the treatment of Cutaneous Leishmaniasis.

6 Oct 2009

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

AVANIR Pharmaceuticals, Inc. today announced it will present detailed data from the Phase III confirmatory STAR trial in the treatment of pseudobulbar affect (PBA) at the 3rd World Congress on Controversies in Neurology (CONy) in Prague, Czech Republic on October 8 - 11, 2009 and the American Neurological Association (ANA) 134th Annual Meeting in Baltimore, MD on October 11 - 14, 2009.

6 Oct 2009

pDCs promote growth and survival of malignant myeloma cells

Multiple myeloma cancer cells thwart many of the drugs used against them by causing nearby cells to turn traitor - to switch from defending the body against disease to shielding the myeloma cells from harm - Dana-Farber Cancer Institute scientists report in the October issue of Cancer Cell.

6 Oct 2009

iMedicor to market Access Pharmaceuticals' MuGard in North America

ACCESS PHARMACEUTICALS, INC. announced today that it had signed an agreement with iMedicor for the North American commercial launch of MuGard, its FDA approved mucoadhesive oral rinse for the management of oral mucositis and stomatitis caused by radiotherapy and/or chemotherapy.

6 Oct 2009

U.S. market for diabetes drugs, devices and monitoring systems to reach over $55 billion by 2016

According to a new report series by iData Research, the leading global authority in medical device, dental and pharmaceutical market research, the U.S. market for diabetes drugs, devices and monitoring systems will reach over $55 billion by 2016, tripling in value.

6 Oct 2009

Resveratrol may help improve diet-induced diabetes

Resveratrol, a molecule found in red grapes, has been shown to improve diabetes when delivered orally to rodents. Until now, however, little has been known about how these beneficial changes are mediated in the body.

6 Oct 2009

Scientists expand their fleet of genomic next-generation sequencing technology to study about cancer

Scientists from the Baylor College of Medicine Human Genome Sequencing Center (HGSC) are expanding their fleet of advanced genomic next-generation sequencing technology from Applied Biosystems, part of Life Technologies Corporation to accelerate their studies of the genetic underpinnings of cancer and other complex human diseases.

6 Oct 2009

Fat and muscle mass may contribute to diabetes risk

Fat and muscle mass, as potentially determined by a person's ethnic background, may contribute to diabetes risk, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

6 Oct 2009

The latest medication to treat schizophrenia "ABILIFY" launched in Canada

A new treatment option for Canadians with schizophrenia, ABILIFY(TM) (aripiprazole), is now available in Canada. For those living with this lifelong disease who may be struggling with a treatment that doesn't work for them or with side effects that are difficult to tolerate, ABILIFY offers efficacy and good safety and tolerability with limited impact on weight, blood sugar and lipids - significant clinical benefits that may help patients stay on treatment longer.

6 Oct 2009

Triage NGAL Test allows early identification of AKI in ICU patients

According to a new study now available online, and to be published in an upcoming issue of the Journal of Critical Care, bedside testing for a blood biomarker called neutrophil gelatinase-associated lipocalin (NGAL) in patients being admitted to the intensive care unit can help to identify patients at risk for acute kidney injury (AKI).

6 Oct 2009

FDA Advisory Committee approves Peginterferon alfa-2b for treating metastatic melanoma

Enzon Pharmaceuticals, Inc. today announced that the FDA Oncologic Drug Advisory Committee voted in favor of recommending approval of PEGINTRON® as a treatment in addition to surgery in patients with metastatic melanoma.

6 Oct 2009

16 Canadian students living with chronic illness to receive UCBeyond Scholarships

What would you do if you were faced with a chronic illness? Would you walk across Canada to raise awareness for Crohn's disease, build houses in developing countries despite physical pain or dedicate your career to educating young people living with the same disease as you?

6 Oct 2009

Kennedy Krieger Institute announces the results of largest ever twin study of ASDs

Kennedy Krieger Institute announced today new study results from the largest ever twin study that confirm the role genetics plays in autism spectrum disorders (ASDs), but also suggest that environmental factors play a role.

6 Oct 2009

OncoGenex' OGX-011 receives additional FDA Fast Track Designation for treating metastatic prostate cancer

OncoGenex Pharmaceuticals, Inc. announced today that OGX-011, also known as custirsen sodium, received an additional Fast Track Designation from the U.S. Food & Drug Administration (FDA) for progressive metastatic prostate cancer in combination with first-line docetaxel treatment.

6 Oct 2009

Medical Condition News

$16 million federal stimulus funds establish Seattle as national hub for cancer research

Cognitive behavioral therapy effective for bulimia and binge eating disorders

FDA provides 510(k) clearance for Boston Scientific's WallFlex Biliary RX covered stents

US Army grants BioDelivery Sciences $1.3M for investigating Bioral Amphotericin B

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

pDCs promote growth and survival of malignant myeloma cells

iMedicor to market Access Pharmaceuticals' MuGard in North America

U.S. market for diabetes drugs, devices and monitoring systems to reach over $55 billion by 2016

Resveratrol may help improve diet-induced diabetes

Scientists expand their fleet of genomic next-generation sequencing technology to study about cancer

Fat and muscle mass may contribute to diabetes risk

The latest medication to treat schizophrenia "ABILIFY" launched in Canada

Triage NGAL Test allows early identification of AKI in ICU patients

FDA Advisory Committee approves Peginterferon alfa-2b for treating metastatic melanoma

16 Canadian students living with chronic illness to receive UCBeyond Scholarships

Kennedy Krieger Institute announces the results of largest ever twin study of ASDs

OncoGenex' OGX-011 receives additional FDA Fast Track Designation for treating metastatic prostate cancer

Brain study of people with psychopathic personality disorder

Premera Blue Cross supports cancer diagnostics study

Pepsico's initiative to reduce obesity, joins HWCF

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News